
ãæ¥æ¬ãæäžäž»ïŒæªæ¿èªã®ææ°æ²»çãDFPPïŒè¡æ¶²æŽæ¿¯ïŒè¡æŒ¿ã濟éããæå³ïŒãã§ã³ããã¯ã¯ãã³åŸéºçã®æ²»çã«æãã
ðð¥ðšðšð ððð®ð§ðð«ð² ð¢ð§ ððð©ðð§: ðððð¥ ððð¥ð¢ðð ððšð« ððððð¢ð§ð-ðð§ð£ð®ð«ðð?ð©ž
â âSudden And Unexpectedâ (@toobaffled) April 16, 2026
People are traveling to Japan for a promising treatment the FDA hasnât approved in the United States (yet) due to regulations.
DFPP (Double Filtration Plasmapheresis) is an⊠pic.twitter.com/eTUVPtKGhk
æ¥æ¬ã§ã®ãè¡æ¶²æŽæ¿¯ãïŒã¯ã¯ãã³åŸéºçãžã®çã®ææžãšãªããïŒ ð©ž
ç±³åœã§ã¯èŠå¶ã«ããFDAïŒç±³é£åå»è¬åå±ïŒãïŒãŸã ïŒæ¿èªããŠããªããå°æ¥ææãªæ²»çæ³ãæ±ããŠäººã ãæ¥æ¬ã蚪ããŠããŸãã
DFPPïŒäºé濟éè¡æŒ¿äº€æçæ³ïŒã¯ãæ¥æ¬ãã¢ãžã¢ã®äžéšã§ãèªå·±å ç«çŸæ£ãç¥çµçŸæ£ã代è¬ç°åžžã«å¯ŸããŠåºãçšããããŠãã確ç«ãããè¡æ¶²æµåæè¡ã§ãã
ããã¯å¯éåè·¯å ã§è¡ããããã€ãã¯ãªãè¡æ¶²ã®æŽæ¿¯ãã®ããã«æ©èœããŸããè¡æ¶²ãæ¡åããè¡æŒ¿ãåé¢ããŠ2ã€ã®ç¹æ®ãªãã£ã«ã¿ãŒã«éãããšã§ãæå®³ãªååïŒèªå·±æäœããµã€ãã«ã€ã³ãå ç«è€åäœããããŠæœåšçãªã¹ãã€ã¯é¢é£ã¢ããã€ããªã©ïŒãåãé€ããæŽæµãããè¡æ¶²ãæ£è ã®äœå ã«æ»ããŸãããããŒããã®è¡æŒ¿ãå¿ èŠãšããªãã®ãç¹åŸŽã§ãã
幹现èç±æ¥ã®æé·å åã®æ³šå ¥ãšçµã¿åããããããšãå€ããã®ãããã³ã«ã¯ãäœå¹ŽãèŠããã§ãã人ã ã«çã®ææžãäžããŠãããäžéšã®ã¯ãªããã¯ã§ã¯ãæ°åã³ããã¯ã¯ãã³ã®åŸéºçã«èŠãã人ã ããmRNAã¹ãã€ã¯ã¿ã³ãã¯è³ªãé€å»ããããã«äœ¿çšãããŠããŸãã
æ¥æ¬ã§ã®å®éã®æ£è äœéšã«ã€ããŠã¯ããã¡ãã®èšäºãã芧ãã ããïŒ
europereloaded.com/has-japan-foun...
âäºéèæ¿Ÿéè¡æŒ¿äº€ææ³ïŒDFPPïŒDouble Filtration PlasmapheresisïŒ
èåè¡æŒ¿åé¢åšãçšããŠè¡æ¶²ããè¡æŒ¿ãåé¢ããè¡æŒ¿äžã«ååšããç å é¢é£ç©è³ªãªã©ãé€å»ããããã«äºæ¬¡æ¿ŸéèãééãããŸããäºæ¬¡æ¿Ÿéèãééã§ããªãç©è³ªã¯é€å»ãããééã§ããç©è³ªã¯äœå ã«æ»ãããŸããäœã¢ã«ããã³è¡çäºé²ã«ã¢ã«ããã³æ°Žæº¶æ¶²ãè£å ããŸãã

Has Japan Found the Cure for Covid Vax Injury?ïŒæ¥æ¬ã¯æ°åã³ãããŠã€ã«ã¹ææçã«ããè¢«å®³ã®æ²»çæ³ãèŠã€ããã®ã?ïŒ
April 15, 2026 GOVERNMENT, HEALTH, Spotlight, WORLD 0
ERç·šéè æ³šïŒ ãã®æ å ±ãäºå®ã§ããã°ãå ¬è¡šããªãããã«ã¯ãããªãã»ã©æ¥µããŠéèŠãæ¥æ¬ã«ã¯ãæ°åã³ããmRNAã¯ã¯ãã³ã«ãã£ãŠè¢«å®³ãåãã人ã ã«å¯Ÿããé©åãªæ²»çæ³ãããããã ãããã¯ãåºæ¬çã«ã¯äžçš®ã®ãè¡æ¶²æŽæ¿¯ããšåŒã¹ããã®ã
éãæãçãç·æ§ã¯ãããŒããšåŒã°ããŠãããæ¥æ¬ã®æ±æžå·ç é¢ã®12çªç®ã14çªç®ã®æ£è ã§ãããšæãããããããŒãã¯ãã©ã³ãæ°ããã¡ãŠãæ°ãéé£ããŠããããããã¯äžåœãªãã®ã§ã¯ãªãã®ã ã西åŽè«žåœã¯ã極ããŠé倧ãªé埳çåé¡ãæ±ããŠããã
GREAT NEWS for the vaccine-injured in JapanâŠ
â Liz Churchill (@liz_churchill10) April 14, 2026
âThis is life-changingâŠI have my life backâŠâ
Japan is HEALING vaccine-injured patients with DFPP + stem cell therapy.
Dr. Mary Bowden has already sent 2 patients who got their lives back.
THANK YOU ðð» https://t.co/qTVafHoh6P
I am currently undergoing Life saving Treatment from horrific damage from the Pfizer COVID 19 vaccines. I am here in Japan at Edogawa Hospital. The Treatment is to clear spike proteins, amyloid blood clots, autoantibodies, and misfolding proteins from the blood using dual⊠pic.twitter.com/FlM6PPRfrR
â KenCaptn20114 (@KenCaptn20114) April 15, 2026
ç§ã¯çŸåšããã¡ã€ã¶ãŒè£œCOVID-19ã¯ã¯ãã³ã«ããæããã被害ããåœãæãããã®æ²»çãåããŠããŸããä»ãæ¥æ¬ã®æ±æžå·ç é¢ã«ããŸãã
æ²»çå 容ã¯ãäºé濟éè¡æŒ¿äº€æçæ³ïŒDFPPïŒãçšããŠè¡æ¶²ããã¹ãã€ã¯ã¿ã³ãã¯è³ªãã¢ããã€ãè¡æ ãèªå·±æäœãããã³ç°åžžã«æãç³ãŸããã¿ã³ãã¯è³ªãé€å»ããããã«ãããªã°ããŒã¹ïŒpre-growthïŒã幹现èãçšããŠèªèº«ã®èº«äœã®ä¿®åŸ©ãå©ãããšãããã®ã§ãããã®æ²»çãæäŸããŠããã®ã¯ãå°çäžã§ããã ãã§ããç§ã¯ããã§14çªç®ã®æ£è ã§ããããŸãã«å¥è·¡ãšããèšãããã®ãªãå æ¯ãç®ã®åœããã«ããŠããŸãã
ç§ããããžéãåºããŠãããçŽ æŽãããç§åŠè ã®ã±ãã³ã»ãã±ã¢ã³ïŒKevin McCairnïŒæ°ãšã¡ã¢ãªãŒã»ã¿ãªãŒã»ããŒãã³ïŒMary Talley BowdenïŒåå£«ã«æè¬ããŸããæ£è ãã¡ãæ¯ãå¹ãè¿ããŠããæ§åãèŠãã®ã¯ãæ¬åœã«å¥è·¡ã®ããã§ãããããã®çŽ æŽãããçåè ãã¡ãšçµãæ·±ããããšã¯ãç§ã®äººçã§æãä¿¡ããããªããããªçµéšãšãªã£ãŠããŸãã
å¿èãžã®ãã¡ãŒãžãé床ã®è¡æ ãå€èåšäžå šãäžæ¢ç¥çµç³»ãžã®ãã¡ãŒãžãè³æå·ã埮å°è¡ç®¡çŸæ£ãèã»é£éã»èºã»å¯éŒ»è ããã®åºè¡ãç²ç¶è ºã®ç Žå£ãšæåºãå¯éŒ»è è ã®ç Žå£ããã»ããŠç ãèçãç®èã®äžã§åºè¡ããŠæœ°çã«ãªãçç¶ããããŠæ¥µãã€ãã¯å°ç¹ç¶ãã¥ãŒããããŒãäžããŠããããã¡ã€ã¶ãŒã«ãç¹å¥ãªã瀌ãèšããããšæããŸãã
ã¯ã¯ãã³åŸéºçã«æççãªãã¹ãŠã®äººãžãç§ã®æ€æ»çµæãããã®å šè²ã100%ç©èªã£ãŠããŸããç§åŠã«åŸã£ãŠãã ããïŒFollow the scienceïŒã
ãã¡ã€ã¶ãŒè£œã¯ã¯ãã³ã«ããæ·±å»ãªå¥åº·è¢«å®³ã蚎ãããããç±³åœäººç·æ§ã®å£°ãä»ã倧ããªæ³šç®ãéããŠããŸããð⊠pic.twitter.com/7oKQx9KLv6
â ããã (@w2skwn3) April 15, 2026


https://x.com/KevinMcCairnPhD/status/2044075993275740533

It's a privilege to be doing this work with@KevinMcCairnPhD https://t.co/9yIKDQIYCl
â Charles Rixey, MA MBA (c) (@CharlesRixey) April 15, 2026
REAL HOPE FOR THE C19 VACCINE INJURED! The Blood Cleanup Breakthrough Has Arrivedð©žð¯ðµ
â Vaccine Safety Research Foundation (@VacSafety) April 14, 2026
While the West slow-walks treatments, Japan is using "Double Filtration" to save lives.
New clinical reports from Japan are showing remarkable recoveries for those suffering from vaccine⊠pic.twitter.com/rmQAZtCpsN
西åŽè«žåœãæ²»çæ³ã®å°å ¥ãé ãããŠããäžæ¹ã§ãæ¥æ¬ã¯åœãæãããã«ãäºé濟éããæŽ»çšããŠããŸããæ¥æ¬ããã®æ°ããèšåºå ±åã¯ãã¯ã¯ãã³åŸéºçããã³ã°COVIDïŒæ°åã³ããåŸéºçïŒã«èŠãã人ã ã®é©ãã¹ãå埩ã瀺ããŠããŸãããã®ç§å¯ã¯äœã§ããããïŒããã¯ãäºé濟éè¡æŒ¿äº€æçæ³ïŒDFPPïŒã§ãã
ããããã€ãã¯ãªãè¡æ¶²ã®æŽæ¿¯ããšèããŠãã ãããDFPPã¯åã«è¡æŒ¿ã亀æããã ãã§ãªããäºéãã£ã«ã¿ãŒã·ã¹ãã ã䜿çšããŠã以äžã®ãã®ãç¹ç°çã«æšçãšããç©ççã«é€å»ããŸããè¡æ¶²äžã埪ç°ããæ¯æ§ã®ããã¹ãã€ã¯ã¿ã³ãã¯è³ªã
èåšãžã®é žçŽ äŸçµŠã鮿ãããã£ããªãã€ã埮å°è¡æ ã
äœãèªåèªèº«ãæ»æããåå ãšãªãèªå·±æäœã
äœå¹Žãå¯ãããã ã£ãæ£è ãã¡ããã€ãã«ãé§ãæŽãããããªãæèŠãå ±åããŠããŸãããã¬ã€ã³ãã©ã°ãè§£æ¶ãããå§åçãªç²åŽæãæ¶ãå»ã£ãã®ã§ãããã¡ãã®å»åŠçãããã¹ãŠã¯æ°ã®ããã ããšèšã£ãŠæ£è ãã¬ã¹ã©ã€ãã£ã³ã°ïŒå¿ççèåŸ ïŒãç¶ããŠããéã«ãæ¥æ¬ã®ã¯ãªããã¯ã¯ãæ¯æ§ã®åå ãåãé€ãã°äœã¯ã€ãã«æ²»çã§ãããšããããšã蚌æããŠããŸãã
西åŽè«žåœã¯ãç©èªïŒãã©ãã£ãïŒã§ã¯ãªããç§åŠã«åŸãã¹ãæã§ãããã®éèŠãªç ç©¶ã®å€ããåãæããŠãã @KevinMcCairnPhD ã«æ¬æã衚ããŸãã
Hope for the vaccine-injured in Japan. Iâve had 2 patients undergo DFPP + IV stem cell growth factors, and weâre getting ready to launch a fundraiser to bring the treatment to the US. https://t.co/g8rvW8hVtQ
â Mary Talley Bowden MD (@MaryBowdenMD) April 14, 2026
Robert is the 12th patient at this hospital.
â Katsuhiko Fukuda MD PhD çŠç° å 圊 (@eitchan) April 14, 2026
When he first arrived in Japan, he was in a state of severe disability. However, thanks to SGF stem cell therapy and plasma replacement therapy, he has been reborn and regained his lifeâto the degree that he can now go hiking with hisâŠ
ãããŒãã¯ãã®ç é¢ã§12çªç®ã®æ£è ã§ãã 圌ãåããŠæ¥æ¬ã«å°çãããšããåœŒã¯æ·±å»ãªéå®³ç¶æ ã«ãããŸãããããããSGF幹现èçæ³ãšè¡æŒ¿äº€æçæ³ã®ãããã§ã圌ã¯çãŸãå€ããã人çãåãæ»ããŸãããä»ã§ã¯åŠ»ãšäžç·ã«ãã€ãã³ã°ã«è¡ããã»ã©ã«ãªã£ãã®ã§ãïŒâ€ïž
æ¥æ¬ã®æ£è ã«å¯ŸããŠãmRNAã¯ã¯ãã³ã®è¢«å®³ãããã³ã°ã»ã¯ã¯ãã³åŸéºçïŒlong-VAXïŒãããã®å埩ã®ããã«ã幹现èçæ³ãè¡æŒ¿ã¢ãã§ã¬ãŒã·ã¹ïŒè¡æŒ¿åé¢äº€ææ³ïŒãšãã£ã確ç«ãããæ²»çæ³ã瀺ãããŠããã«ããããããã åœãã®å¹³åã«å®äœããŠããã»ãšãã©ã®å»åž«ãã¡ã¯ãæ¥æ¬ãæå€§ã®ç ç²è ãåºããŠããåœã§ããããšãããªãã¡ãã€ãªããã«ãã£ãŠåŒãèµ·ããããç¬¬äžæ¬¡äžç倧æŠã®çã£åªäžã«ããæšçã§ããããšãèªèŠããŠããŸããïŒïŒ

æ¥æ¬ã®æ±æžå·ã«ããç é¢ããæ°åã³ããã¯ã¯ãã³åŸéºçããã³åŸéºçïŒLong COVIDïŒã®æ²»çã«ã±ãã³ã»ãã±ã¢ã³ã®DFPPãšå¹¹çްèæé·å åãããã³ã«ãé©çš
æçµæŽæ°ïŒ28åå
æ¥æ¬ã®æ±æžå·ã«ããç é¢ããæ°åã³ããã¯ã¯ãã³åŸéºçãåŸéºçïŒLong COVIDïŒã«èŠããæ£è ãæ²»çãããããã±ãã³ã»ãã±ã¢ã³å士ã®ãæ±æžå·ã»ãã±ã¢ã³ã»ãããã³ã«ããæ¡çšããŠããŸãããã®ãããã³ã«ã¯ãäºé濟éè¡æŒ¿äº€æçæ³ïŒDFPPïŒã«ãã£ãŠã¢ããã€ããã¹ãã€ã¯ã¿ã³ãã¯è³ªãé€å»ãããã®åŸã«å¹¹çްèæé·å åãçšãããã®ã§ããæ£è ã®ãããŒãã»ãã³ãœã³æ°ã¯4åã®DFPPæ²»çãåãã2021幎以æ¥ã®èŠãã¿ããè§£æŸãããå¥åº·ç¶æ ãå®å šã«å埩ãããšå ±åããŠããŸãã
ïŒãã®ã¹ããŒãªãŒã¯Xäžã®æçš¿ããŸãšãããã®ã§ãããæéã®çµéãšãšãã«å å®¹ãæŽæ°ãããå¯èœæ§ããããŸããGrokã¯ééããç¯ãããšããããããåºåã確èªããŠãã ãããïŒ

hey all my Q friends, numerology and astrology peeps
â Lyndsey, RN ðð (@HouseLyndseyRN) April 15, 2026
can you educate me of the significance of #17
i will be research patient number 17 on april 21st at 9:30 am Tokyo time Japan
does this fit or help anything info wise?
tia pic.twitter.com/l9Us1R8Zo4
In case you donât know her, This is Lyndsey, who was vaccine injured severely, and sheâs still making spike protein in her body. Sheâs in Japan after the X community raised enough money to send her and sheâs having plasmaforesis to filter of all of the bad stuff - toxins - that⊠https://t.co/bx957gZvfx
â Dr. Chris Baker (@drchrisbaker) April 21, 2026
圌女ããåç¥ãªãæ¹ã®ããã«ç޹ä»ãããšããã¡ãã¯ãªã³ãžãŒããã§ãã圌女ã¯ã¯ã¯ãã³ã«ãã£ãŠæ·±å»ãªå¯åå¿ïŒã¯ã¯ãã³å·å®³ïŒãè² ããä»ãäœå ã§ã¹ãã€ã¯ã¿ã³ãã¯è³ªãäœããç¶ããŠããŸããXïŒæ§TwitterïŒã®ã³ãã¥ããã£ã圌女ãéãåºãããã®ååãªè³éãéããããšã§ã圌女ã¯çŸå𿥿¬ã«æ»åšããŠããŸãããããŠãã¯ã¯ãã³ã«ãã£ãŠè¡æµäžã«çæããããæªããã®ïŒæ¯çŽ ïŒãããã¹ãŠãéããŠåãé€ããããè¡æŒ¿äº€æçæ³ïŒãã©ã¹ããã§ã¬ãŒã·ã¹ïŒãåããŠããŸãã
ããã¯éåžžã«ãšããµã€ãã£ã³ã°ãªããšã§ãããã®ãããªããšãèµ·ããŠããã®ãç®ã®åœããã«ããã®ã¯ããã®äžãªãåºæ¿çã§ããçŸåšãã¢ã¡ãªã«åœå ã®ã°ã«ãŒããããã¹ãŠã®ã¯ã¯ãã³è¢«å®³è ã®ããã«ãã®æ²»çæ³ãã¢ã¡ãªã«ã«å°å ¥ã§ãããããIRBïŒå«çå§å¡äŒïŒãžã®ææ¡ãšèš±å¯ãåŸãããã«åãçµãã§ããŸãã
Hypovolemic Shock couldnt hold me down
â Lyndsey, RN ðð (@HouseLyndseyRN) April 21, 2026
im home, in my bed and stable
below are my pre and post of my plasma
my labs will be traveling to the lab tom and will have before and after panels of cytokines, immune markers etc-
the filters itself went to patho so i didnt get to⊠pic.twitter.com/PqA4se7Otc
ãªã³ãžãŒãçè·åž«ïŒRNïŒ
@HouseLyndseyRN · 9æéå
äœè¡ç³æ§ã·ã§ãã¯ãç§ãæãã€ããããšã¯ã§ããŸããã§ããã
åž°å® ããŠãèªåã®ãããã§å®éã«ããŠããŸããç¶æ ã¯å®å®ããŠããŸãã
以äžã¯ãè¡æŒ¿äº€æïŒãã©ãºããã§ã¬ãŒã·ã¹ïŒã®ååŸã®ç§ã®è¡æŒ¿ã®æ§åã§ãã
ç§ã®æ€äœã¯ææ¥ã©ãã«éããããµã€ãã«ã€ã³ãå ç«ããŒã«ãŒãªã©ã®ããã©ãŒã»ã¢ãã¿ãŒã®ããã«èª¿æ»ãè¡ãããäºå®ã§ãã
ãã£ã«ã¿ãŒèªäœã¯ç çæ€æ»ã«åãããããããã®åçã¯æ®ããŸããã§ããã
å·ŠåŽãæ²»çåã®ç§ã®è¡æŒ¿ã§ãã
å³åŽãæ²»çåŸã®ç§ã®è¡æŒ¿ã§ãã
容äœãå®å®ãç å®€ã«æ»ã£ãåŸã10ccã®å¹¹çްèæé·å åãš1ãªããã«ã®ççé£å¡©æ°Žã®æäžãåããŸããã
ä»ã®ãšããâŠâŠè³ã®é§ïŒãã¬ã€ã³ãã©ã°ïŒã¯åçã«æŽããŠæ¹åããæè¶³ã®ç¥çµé害ãè¯ããªã£ãŠããŸãã
æ®æ®µã¯POTSïŒäœäœæ§é »èçå矀ïŒã®åœ±é¿ã§90å°ã ã£ãå®éæå¿ææ°ããä»ã¯70å°ã«ãªã£ãŠããŸããç«ã¡äžãã£ãæã®ããŸããæ¯åãããªããç«äœã§ã®æé«å¿ææ°ã¯108ã§ããã以åã¯ç«ã¡äžãããš120ã170ã®ç¯å²ã ã£ãã®ã§ã倧ããªå€åã§ãã
è¡å§ã120/79ãšãã»ãŒæç§æžéãã§æ£åžžã§ãã
çããã®åžæã«ãªããŸãããã«ã
ããžã§å¹ããŠãã

ãæ¥æ¬ð¯ðµäŒ æ¥éæŒçæ¢å€æ¥åâŒïžãð
â æ¥æ¬å€§åèŸ²å ŽïŒç¹å»ºç³è¯·äžïŒ (@DAIWA7777777) April 21, 2026
çŸåœçICU/ERæ€å£«æ¥åäºæ±æ·å·å»é¢Â·å è€æ£äºéå»çè¿è¡çè¡æµè¿æ»€æ²»çïŒäººçåçäºæ¹åã
McCairn Protocol Japan ç ç©¶æ£è #17
è¯·çæ²»çååçè¡æµç §çïŒå·ŠïŒæ²»çåïŒå³ïŒæ²»çåïŒã
ã»10ccçå¹²ç»èçé¿å åïŒ1Lçççæ°Žæäž
ã»å®éæ¶å¿ç 90å€ â æ¥å§éè³70å€âŠ https://t.co/xDwcHDugXo pic.twitter.com/6ZksRBj3y6
ãæ¥æ¬ããè¡æã®ååŸ©å ±åãå±ããŸããã
ã¢ã¡ãªã«ã®ICU/ERçè·åž«ããæ±æžå·ç é¢ã»å è€æ£äºéå»åž«ã«ããè¡æŒ¿ãã£ã«ã¿ãªã³ã°æ²»çãåãã人çãå€ãããŸããã
McCairn Protocol Japan
ç ç©¶æ£è #17
æ²»çååŸã®è¡æŒ¿åçãã芧ãã ããïŒå·ŠïŒæ²»çåïŒå³ïŒæ²»çåŸïŒã
ã»10ccã®å¹¹çްèæé·å åïŒ1Lã®ççé£å¡©æ°Žæäž
ã»å®éæå¿ææ° 90å° â æ¥æ¿ã«70å°å°ãžäœäž
ã»POTSçç¶ãé¡èã«æ¹å
ã»ãã¬ã€ã³ãã©ã°ãå€§å¹ ã«è»œæžãç¥çµé害ãç·©å
ã»äœè¡éæ§ã·ã§ãã¯ããè±ããç¡äºéé¢ïŒ ããã¯åãªããå埩ãã§ã¯ãããŸããã ããã¯æ¥æ¬å»çãäžçã®é£ç ã«çå£ã«æã蚌ã§ãã
å è€æ£äºéå»åž«ãæ¬åœã«ããããšãããããŸãã
ãã®ãããªæ²»çãåŸ ã€äººã¯ãæ¥æ¬ãäžçäžã§ãŸã ãŸã ããããããŸãã
äžå»ãæ©ãå€ãã®æ£è ãããæ©æµãåããããããšãé¡ããŸãã
ãããªææãåããããããªããŠçµ¶å¯Ÿã«èš±ããŸããã
æ¡æ£ã®ãæäŒãããé¡ãããŸãã
my resting heart rate today yall
â Lyndsey, RN ðð (@HouseLyndseyRN) April 22, 2026
78 beats per minute
i havent had a normal resting heart rate this low in 5 years pic.twitter.com/6NFIdZorJ9
仿¥ã®å®éæå¿ææ°ãèŠãŠããã¿ããªã
1åéã«78åã
ãã5å¹Žãæ£åžžãªå®éæå¿ææ°ããããªã«äœããªã£ãããšãªããŠãªãã£ãã®ã«ã
So happy for you Lyndsey and grateful that the country Japan has provided for our mRNA vax injured since our US government and medical industrial complex refuses to. Wouldnt it be nice if this motivates @POTUS to start offering this treatment here and STOP mRNA altogether!!! https://t.co/LpeNOMIWxP
â Fitz the Galatian (@Fitz4Liberty) April 22, 2026
ãªã³ãžãŒãæ¬åœã«ããã£ãããã¢ã¡ãªã«æ¿åºãå»åŠçã»ç£æ¥çã®è€åäœãæçµ¶ããäžã§ãæ¥æ¬ãšããåœãç§ãã¡ã®mRNAã¯ã¯ãã³åŸéºçæ£è ïŒvax injuredïŒã«æãå·®ã䌞ã¹ãŠãããŠããããšã«æè¬ããŸããããããã£ããã§å€§çµ±é ããã¡ãã§ãæ²»çãæäŸãå§ããmRNAèªäœãå®å šã«äžæ¢ããæ°ã«ãªã£ãŠããããæé«ãªã®ã«ïŒïŒïŒ
more pics of my plasma samples pre and post treatment
â Lyndsey, RN ðð (@HouseLyndseyRN) April 21, 2026
pre procedure is orange and cloudy (right)
post procedure is yellow and clear (left)
thats after one session and 1 Liter of my blood filtered
also heres a pic of where my IV was inserted into my neck- its sore but other⊠pic.twitter.com/ucbnqn0wNQ
æ²»çååŸã®è¡æŒ¿ãµã³ãã«ã®åçããã£ãšèŒãããã
åŠçœ®åã¯ãªã¬ã³ãžè²ã§æ¿ã£ãŠããæ¹ïŒå³ïŒã
åŠçœ®åŸã¯é»è²ããŠæŸãã§ããæ¹ïŒå·ŠïŒã ãã
ããã¯1åã®ã»ãã·ã§ã³ã§ã1ãªããã«ã®è¡æ¶²ããéããåŸã®çµæã
ããšãéŠã«ç¹æ»Žã®éãåºããç®æã®åçãèŒããŠããããçã¿ã¯ãããã©ããã以å€ã«ææã®å åã¯ãªãã
æ€äœã¯ä»æ¥ãç 究宀ã«éã°ããäºå®ãçµæãåºãããŸãæçš¿ãããã
仿¥ã®ååŸã¯ã¯ãªããã¯ã«è¡ã£ãŠãè ãã10ccã®å¹¹çްèæé·å åãç¹æ»ŽããŠããã
1æéããšã«äœèª¿ãè¯ããªã£ãŠããã®ãæãããã
ãçè·åž«ã»ãªã³ãžãŒ

æ²»çåŸã®è¡æ¶²ããå·ŠåŽããâ


I've been working with @KevinMcCairnPhD and Edogawa Hospital to coordinate the treatment of our patients.
â Charles Rixey, MA MBA (c) (@CharlesRixey) April 23, 2026
Next Tuesday, I will become patient #18 of our protocol, to treat my own mRNA vax injury symptoms, which led to 22 ER visits/hospital stays over 2.5 years.
In December⊠https://t.co/RO6pnGCnCI
ç§ã¯ã±ãã³ã»ãã±ã¢ã³å士ïŒ@KevinMcCairnPhDïŒããã³æ±æžå·ç é¢ãšååããŠãæ£è ãã¡ã®æ²»çã®èª¿æŽã«ããã£ãŠããŸããã
æ¥é±ã®ç«ææ¥ãç§èªèº«ãæã ã®ãããã³ã«ïŒæ²»çèšç»ïŒãåãã18çªç®ã®æ£è ã«ãªããŸãã2幎åã®éã«22åãã®ææ¥å€æ¥å蚺ãå ¥é¢ãç¹°ãè¿ãåå ãšãªã£ããèªåèªèº«ã®mRNAã¯ã¯ãã³åŸéºçã®çç¶ãæ²»çããããã§ãã
2024幎12æãç§ã®è¡æ¶²ã¯ã±ãã³ã®ç ç©¶å®€ã§æåã«æ€æ»ããããµã³ãã«ãšãªããŸããã圌ãäžçäžãããµã³ãã«ã®åãåããšæ€æ»ãéå§ããéããã®äžã«å«ãŸããŠãããã¢ããã€ãã»ãã€ã¯ãã¯ãããïŒåŸ®å°è¡æ ïŒãããïŒå¿åã§ïŒã©ãã»ã©äºæ ãæªåãåŸããã®å®äŸãšããŠäœ¿çšãããŸããã
å¥ã®ç¬¬2ã®ç 究宀ã§ãçµæã確èªãããç§ã¯è¡æ ã®éã«ãããŠãäžäœ10%ïŒ90ããŒã»ã³ã¿ã€ã«ä»¥äžïŒãã«å ¥ããšå®£åãããŸããã
ä»åãããå ¬ã«æãããã®ã¯ãç§ã®è¡æ¶²ã®æ²»çåã»æ²»çåŸã®å€åããããTwitterïŒXïŒã§å ±æããã€ããã ããã§ãã
ç§ãã¡ã¯ãæ¿åºãæã¿ç¶ããŠãããç§åŠçã»å»åŠçéææ§ãã®ç¢ºä¿ã«å šåãå°œãããŠããŸãã
ç«ææ¥ãç§ã¯åããŠã«ã¡ã©ãæã€åŽã§ã¯ãªããã«ã¡ã©ã®åã«ç«ã€ããšã«ãªããŸãã
Patient #12https://t.co/2uyj1TYlU3
â Charles Rixey, MA MBA (c) (@CharlesRixey) April 23, 2026
Patient #14https://t.co/sLtQ1gB80B
â Charles Rixey, MA MBA (c) (@CharlesRixey) April 23, 2026
Patient #10https://t.co/WYtmBXbTmd
â Charles Rixey, MA MBA (c) (@CharlesRixey) April 23, 2026
Patient #9https://t.co/EHW0IxtkSu
â Charles Rixey, MA MBA (c) (@CharlesRixey) April 23, 2026
taking a shower without getting hot, dizzy, & passing out or being completely tired after is so cool - no more shower chair for me
â Lyndsey, RN ðð (@HouseLyndseyRN) April 24, 2026
its the little things we take for granted
improving daily
brian fog gone
joint pain gone
neuropathy gone
resting heart rate 74
standing heart rate⊠pic.twitter.com/3X9ANg4zzK
æããªã£ãããããŸããããããæèã倱ãããã«ãªã£ãããçµãã£ãåŸã«ç²ãæãŠããããã«ã·ã£ã¯ãŒã济ã³ãããªããŠæé«ãããã·ã£ã¯ãŒãã§ã¢ã¯ãããªãã
åœããåã ãšæã£ãŠãããããªãã¡ãã£ãšããããšã
æ¥ã ãè¯ããªã£ãŠããã
ãã¬ã€ã³ãã©ã°ïŒè³ã®é§ïŒãæ¶ããã
é¢ç¯ã®çã¿ãæ¶ããã
ãã¥ãŒããããŒïŒç¥çµé害ïŒãæ¶ããã
å®éæå¿ææ° 74ã
ã·ã£ã¯ãŒäžã®ç«äœå¿ææ° 108ã
äœãå ã®æ£åžžãªç¶æ ã«æ»ãã€ã€ããã
:) :) :)
So the Yale Listen Study said 709 days per their testing of vaxinjured still having continuous spike production (which I am a participant in this study) and show T cell exhaustion etc
â Lyndsey, RN ðð (@HouseLyndseyRN) February 21, 2025
Well itâs actually longer than that:
My first injection was 12/23/2020 and I havenât stopped⊠pic.twitter.com/VrP2H4P4qx

æãæžå¿µãã¹ãçµæå ç«ç³»ã®æå·ïŒç²åŒïŒæžå°ïŒCD4ãã«ããŒT现èã®æžå°ãããã³CD8ãã©ãŒT现èã®å¢å ïŒãTNFα+ CD8 T现èã®å¢å ã¯ãççæŽ»æ§ã®é«ãŸãã瀺åããŠããããããå ç«èª¿ç¯é害ãçµç¹æå·ãæãå¯èœæ§ãããã
æéã®çµéãšãšãã«å¢å ãããé·æçãªã¹ãã€ã¯ã¿ã³ãã¯è³ªã®ç£ç
圌ããè«æãæåºããããšããäž»èŠãªå»åŠéèªã¯ãã¹ãŠãæ²èŒã®æ€èšãæåŠããã
ããã¥ãŒãšãŒã¯ã»ã¿ã€ã ãºãçŽïŒThe New York TimesïŒã§ãåãäžããããã
ããã¯ãã¯ã¯ãã³ã®å¯åå¿ïŒvaccine injuryïŒãå®åšããããšãèªããããã®è¯ãã¹ã¿ãŒãã§ããã
ãããªãåãçµã¿ãå¿ èŠã ã
1. å ç«ç³»ã®æå·ïŒç²åŒïŒæžå°ã«ã€ããŠ
ãã®èšè¿°ã¯ãå ç«ã·ã¹ãã ã®åžä»€å¡ãšå®è¡éšéã®ãã©ã³ã¹ã厩ããå¶åŸ¡äžèœã«é¥ã£ãŠããç¶æ ãæããŠããã
CD4ãã«ããŒT现èã®æžå°
å
ç«ã®ãåžä»€å¡ãã§ãã现èã®äžè¶³ãæå³ããããããæžå°ãããšããŠã€ã«ã¹çã®å€æµã«å¯Ÿããé©åãªæ»ææä»€ãåºããªããªããææçã«å¯Ÿããæµæåã®äœäžãæãã
CD8ãã©ãŒT现èã®å¢å ãšTNFα+ã®é¢äž
ãå®è¡éšéãã§ããCD8现èãéå°ã«ãªããããã«åŒ·åãªççç©è³ªã§ãããTNFαããæŸåºããã¿ã€ããå¢ããŠããç¶æ
ã ãããã¯ãæ¬æ¥å®ãã¹ãèªåèªèº«ã®çµç¹ãæ»æããéå°ãªççåå¿ãåŒãèµ·ããã
å
ç«èª¿ç¯é害ãšçµç¹æå·
ãã¬ãŒããå¹ããã«æ»æèœåã ããé«ãŸã£ãçµæãæ
¢æ§çãªççãç¶ããå¿èãè¡ç®¡ãªã©ã®å
šèº«ã®çµç¹ãç©ççã«ãã¡ãŒãžãåãããªã¹ã¯ã瀺åããŠããã
---
2. é·æçãªã¹ãã€ã¯ã¿ã³ãã¯è³ªã®ç£çã«ã€ããŠ
éåžžãã¯ã¯ãã³ã®mRNAã¯çæéã§åè§£ãããåæã ãããã®èšè¿°ã¯ãäŸå€çãªæåãã«çŠç¹ãåœãŠãŠããã
ç£çæéã®é·æå
æ¬æ¥ã¯æ°æ¥ãæ°é±éã§æ¶å€±ããã¯ãã®ã¹ãã€ã¯ã¿ã³ãã¯è³ªããæ°ã¶æä»¥äžã«ããã£ãŠäœå
ã§äœããç¶ããŠããå¯èœæ§ãææããŠããã
æ¯æ§ã®ç¶ç¶
ã¹ãã€ã¯ã¿ã³ãã¯è³ªèªäœã«è¡ç®¡å
ç®ãå·ã€ãããªã©ã®æ¯æ§ããããšãã仮説ã«åºã¥ãã°ãé·æéã®ç£çã¯è¡æ çãæ
¢æ§çŸæ£ã®åå ãšãªãç¶ããã
ãã¯ã¯ãã³å¯åå¿ïŒvaccine injuryïŒããšã®é¢é£
ãããŸã§åå äžæãšãããŠããé·æçãªäœèª¿äžè¯ã«å¯Ÿãããäœå
ã«æ®ãã¹ãã€ã¯ã¿ã³ãã¯è³ªãããå£ããå
ç«ãã©ã³ã¹ããšããç©ççãªèšŒæ ãèŠã€ããå§ããããšãæå³ããã
1. CD4ãã«ããŒT现èïŒåžä»€å¡ïŒ
å
ç«ã·ã¹ãã ã«ããããåžä»€å¡ãã®åœ¹å²ãæãã现èã ã
CD4ãã«ããŒT现èã¯ãå
ç«ã·ã¹ãã ã«ããããåžä»€å¡ãã®åœ¹å²ãæ
ã现èã§ããã 倿µïŒãŠã€ã«ã¹ã»çްèãªã©ïŒã䟵å
¥ãããšããŸãæš¹ç¶çްèãªã©ã®æåæç€ºçްèããã®æ
å ±ãåã蟌ã¿ãCD4ãã«ããŒT现èã«æç€ºããã CD4ãã«ããŒT现èã¯ãã®æ
å ±ãåããŠæŽ»æ§åããB现èãCD8ãã©ãŒT现èãªã©ä»ã®å
ç«çްèã«å¯ŸããŠæ»æéå§ã®æç€ºãåºããå
ç«åå¿å
šäœãçµ±çããã
ãã®çްèã倧ããæžå°ãããšãå ç«ç³»ã®èª¿æŽæ©èœãäœäžããææçã«å¯Ÿããæµæåã匱ãŸããããç¶æ ã«ãªãã

ãã®å³ã¯ãT现èãæŽ»æ§åãããææãã现èãç Žå£ãããŸã§ã®ããã»ã¹ãèŠèŠåãããã®ã ãå·Šäžã®ãæåæç€ºãããå§ãŸããæèšåãã«é²ãäžé£ã®æµãã解説ã
1. æåæç€º
ç©èªã®å§ãŸãã¯ãæåæç€ºçްèïŒAntigen presenting cellïŒãæµïŒPathogenïŒç
åäœïŒãæããããšããããã ã
æç€ºçްèã¯æµããã©ãã©ã«ãããã®ç Žçã§ããæåïŒAntigenïŒããMHC class IIãšããããçãã«ä¹ããŠçްèã®è¡šé¢ã«å·®ãåºãã
ããããã«ããŒT现èïŒHelper T-cellïŒã®å容äœãèªèããããã®ãšããCD4ãšããååãè£å©ãšããŠçµåããããšã§ãæ
å ±ã®åãæž¡ãã確å®ã«è¡ãããã
2ïŒ
掻æ§åããŠæä»€æ
å ±ãåãåã£ããã«ããŒT现èã¯ã¹ã€ãããå
¥ãããµã€ãã«ã€ã³ïŒCytokinesïŒãšåŒã°ããä¿¡å·ç©è³ªãæŸåºããã ãµã€ãã«ã€ã³ã¯å
ç«ã·ã¹ãã å
šäœãžã®ãåºæåœä»€ãã«çžåœãããã®ã¡ãã»ãŒãžãåãåã£ãå
ç«çްèãæ¬¡ã
ãšæŽ»æ§åãããã ãã®çµæãæ¬¡ã®æ®µéã§ãã CD8ãã©ãŒT现èïŒæ®ºãå±ïŒ ã B现èïŒæäœç£çéšéïŒ ãæ¬æ Œçã«åãå§ããã
3. ãã©ãŒT现èã®æŽ»æ§å
ãµã€ãã«ã€ã³ã®åºæ¿ãåãã现èé害æ§T现èïŒCytotoxic T cellsïŒãã©ãŒT现èïŒã¯æŽ»æ§åããææçŽ°èãç°åžžçްèãæé€ããããã®å®æŠéšéãšããŠå¢æ®ããã æŽ»æ§åãããã©ãŒT现èã¯ãæšçãšãªã现èãçŽæ¥æ»æããèœåãç²åŸããå
ç«åå¿ã®äž»åãšããŠåãã
4. ææçްèã®èªè
掻æ§åãããã©ãŒT现èã¯ãäœå
ãããããŒã«ããŠææãã现èïŒInfected cellïŒãèŠã€ãåºãã
ææçްèã¯ãèªèº«ã®å
éšã«æµãããããšãç¥ããããããMHC class Iãšããå¥ã®ãçã«æåãä¹ããŠæ²ããŠããã
ãã©ãŒT现èã¯CD8ååã䜿ãããã®ææçްèããééããªãæ»æãã¹ãæµãã§ããããšãæçµç¢ºèªããã
5. æ»æãšçŽ°èæ»
ãã©ãŒT现èã¯ãææçްèã«ã¿ãŒã²ãããçµããšãããã©ãŒãªã³ïŒPerforinïŒãã°ã©ã³ã¶ã€ã ïŒGranzymeïŒãšãã£ããæ¯çŽ ããæµã蟌ãã
ããã©ãŒãªã³: ææçްèã®èã«ç©Žãéããããªã«ã
ã°ã©ã³ã¶ã€ã : ãã®ç©Žãã䟵å
¥ãã现èã«ãèªæ±ºïŒã¢ãããŒã·ã¹ïŒããåœããç©è³ªã
ãã®çµæãææçްèã¯ç Žå£ããïŒCell deathïŒãã¢ãããŒã·ã¹å°äœïŒApoptotic bodiesïŒãšãªã£ãŠæé€ãããã
ãã®å³ã¯ããåžä»€å¡ïŒãã«ããŒT现èïŒCD4ïŒãæ å ±ãåãåããäŒä»€ïŒãµã€ãã«ã€ã³ïŒãé£ã°ããŠãå®è¡éšéïŒãã©ãŒT现èïŒCD8ïŒãææçްèãçŽæ¥ä»çããããšãããçŽ°èæ§å ç«ã®å®ç§ãªé£æºãã¬ãŒã瀺ããŠããã®ã ã
2. CD8ãã©ãŒT现èïŒå
µéïŒ
å
ç«ã·ã¹ãã ã«ããããå®è¡éšéïŒå
µéïŒãã ã
ãã«ããŒT现èããã®æä»€ãåãããŠã€ã«ã¹ã«ææãã现èããã现èãçŽæ¥èŠã€ãåºããç Žå£ïŒæ®ºå·ïŒãã圹å²ãæ
ããéåžžã«åŒ·åãªæ»æåãæã€ãããæ¬æ¥ã¯å³å¯ã«å¶åŸ¡ãããŠãããããããå¶åŸ¡äžèœã«ãªããšæ£åžžãªèªåã®çްèãŸã§æ»æããèªå·±å
ç«çŸæ£ã®ãããªçµç¹æå·ãåŒãèµ·ããåå ãšãªãã
3. TNFαïŒãã£ãŒã»ãšãã»ãšãã»ã¢ã«ãã¡ïŒ
èªã¿æ¹: ãã£ãŒã»ãšãã»ãšãã»ã¢ã«ãã¡ïŒTumor Necrosis Factor-alphaã®ç¥ïŒ
æå³: æ¥æ¬èªã§ã¯ãè
«ç壿»å åïŒãã
ããã»ããã»ãããïŒããšåŒã°ããã
现èåå£«ã®æ å ±äŒéã«äœ¿ãããããµã€ãã«ã€ã³ããšããç©è³ªã®äžçš®ã§ããã匷åãªççãåŒãèµ·ããã¹ã€ããã®ãããªåœ¹å²ãæããã
éåžžã¯çŽ°èææãªã©ã«å¯Ÿæããããã«å¿ èŠãªç©è³ªã ããéå°ã«æŸåºããããšæ¿ããççãèªçºãããé¢ç¯ãªãŠãããªã©ã®èªå·±å ç«çŸæ£ã«ãããŠãããã®TNFαãéå°ã«åæ³ãããããšã§ãèªåèªèº«ã®çµç¹ãç Žå£ãããããšãç¥ãããŠããã
ãŸãšã
CD4: æ»æã®åå³ãåºãåžä»€å®ã
CD8: æµãçŽæ¥å©ãå
µéã
TNFα: æ»æçŸå Žã§æããããççã®ç«çš®ãã
ä»åã®ããã¹ãã«ãããTNFα+ CD8 T现èã®å¢å ããšã¯ããéåžžã«æ»ææ§ãé«ããåšå²ã«åŒ·ãççãæãæ£ããå µéããå¶åŸ¡ã倱ã£ãŠå¢æ®ããŠããç¶æ ããæãããããäœå ã®çµç¹æå·ãæããªã¹ã¯ãšããŠæžå¿µãããŠããããã ã
æ¥æ¬ã§ã®ãè¡æ¶²æŽæ¿¯ãïŒã¯ã¯ãã³åŸéºçãžã®ææžãšãªãã
ç±³åœã§ã¯èŠå¶ã«ããFDAããŸã æ¿èªããŠããªãææãªæ²»çæ³ãæ±ãã人ã
ãæ¥æ¬ã蚪ããŠãããDFPPïŒäºé濟éè¡æŒ¿äº€æçæ³ïŒã¯ãæ¥æ¬ãã¢ãžã¢ã®äžéšã§èªå·±å
ç«çŸæ£ãªã©ã«åºãçšããããŠãã確ç«ãããæè¡ã ã
ããã¯å¯éåè·¯å ã§è¡ããããã€ãã¯ãªãè¡æ¶²ã®æŽæ¿¯ãã®ãããªãã®ã ãè¡æ¶²ãæ¡åããŠè¡æŒ¿ãåé¢ãã2ã€ã®ç¹æ®ãã£ã«ã¿ãŒã«éãããšã§ãæå®³ãªååïŒèªå·±æäœããµã€ãã«ã€ã³ãå ç«è€åäœãã¹ãã€ã¯é¢é£ã¢ããã€ããªã©ïŒãé€å»ããæŽæµãããè¡æ¶²ãäœå ãžæ»ãããããŒã®è¡æŒ¿ã¯äžèŠã ã
äžéšã®ã¯ãªããã¯ã§ã¯ãmRNAã¯ã¯ãã³ã®ã¹ãã€ã¯ã¿ã³ãã¯è³ªé€å»ã®ããã«ãã®ãããã³ã«ã䜿çšããé·å¹ŽèŠããã§ãã人ã ã«çã®ææžãäžããŠããã
æ£è
ã®äºäŸãšçŸç¶
ãããŒãã¯ãããæ¥æ¬ã®ç
é¢ã®12çªç®ã®æ£è
ã ãæ¥æ¥æã¯æ·±å»ãªéå®³ç¶æ
ã«ãã£ããã幹现èçæ³ãšè¡æŒ¿äº€æçæ³ã«ããã劻ãšãã€ãã³ã°ã«è¡ããã»ã©ã«å埩ããã
æ¥æ¬ã«ã¯ãããã確ç«ãããæ²»çæ³ãããã«ãããããããå€ãã®å»åž«ã¯åœãã®å¹³åã«å®äœããæ¥æ¬ããã€ãªããã«ãããç¬¬äžæ¬¡äžç倧æŠãã®æšçãšãªããæå€§ã®ç ç²è ãåºããŠããäºå®ã«æ°ã¥ããŠããªãã
西åŽè«žåœãžã®æèš
西åŽè«žåœãæ²»çã®å°å
¥ãé
ãããŠããéã«ãæ¥æ¬ã®ã¯ãªããã¯ã¯ãæ¯æ§ã®åå ãåãé€ãã°äœã¯æ²»çãããããšã蚌æããŠãããé§ãæŽããããã«ãã¬ã€ã³ãã©ã°ãç²åŽãè§£æ¶ãããšããå ±åãçžæ¬¡ãã§ãããä»ãããã©ãã£ãïŒç©èªïŒã§ã¯ãªããç§åŠã«åŸãã¹ãæã ã
mRNAã¯ã¯ãã³ã®ãã¹ãã€ã¯ã¿ã³ãã¯è³ªãã«ã€ããŠè§£èª¬ããã
ã¹ãã€ã¯ã¿ã³ãã¯è³ªãšã¯äœã
ã¹ãã€ã¯ã¿ã³ãã¯è³ªãšã¯ãæ°åã³ãããŠã€ã«ã¹ïŒSARS-CoV-2ïŒã®è¡šé¢ã«çªãåºãŠãããçå ã®ããã²ïŒæ£ïŒãã®ãããªçªèµ·ã®ããšã ã
ãã®ã¿ã³ãã¯è³ªã«ã¯ã人éã®çްè衚é¢ã«ãããACE2å容äœããšããéµç©Žã«çµåãããããã°ãéµãã®ãããªåœ¹å²ãããããŠã€ã«ã¹ã¯ãã®éµã䜿ã£ãŠäººéã®çްèå ã«äŸµå ¥ããææãæç«ãããã
mRNAã¯ã¯ãã³ã®äžã§ã®åœ¹å²
mRNAã¯ã¯ãã³ã¯ããŠã€ã«ã¹ãã®ãã®ãäœå
ã«å
¥ããã®ã§ã¯ãªãããã®ã¹ãã€ã¯ã¿ã³ãã¯è³ªã®ãèšèšå³ïŒéºäŒæ
å ±ïŒãã ããäœå
ã«å±ããã
èšèšå³ã®å°å
¥: ã¯ã¯ãã³ãæ¥çš®ãããšãçè现èã«ã¹ãã€ã¯ã¿ã³ãã¯è³ªã®èšèšå³ïŒmRNAïŒãåã蟌ãŸããã
äœå
ã§è£œé : èªåèªèº«ã®çްèãããã®èšèšå³ãåºã«äžæçã«ã¹ãã€ã¯ã¿ã³ãã¯è³ªïŒãŠã€ã«ã¹ã®äžéšã®ã¿ïŒãäœãåºãã
å
ç«ã®åŠç¿: å
ç«ã·ã¹ãã ããäœãåºããããç°ç©ïŒã¹ãã€ã¯ã¿ã³ãã¯è³ªïŒããèªèããããã«å¯ŸããæŠåšïŒæäœïŒãæ»æéšéïŒT现èïŒãæºåããã
宿Šãžã®åã: åŸæ¥ãæ¬ç©ã®ãŠã€ã«ã¹ã䟵å
¥ããŠããéãå
ç«ã·ã¹ãã ãå³åº§ã«ã¹ãã€ã¯ã¿ã³ãã¯è³ªïŒéµïŒããããã¯ããææãéçåãé²ãã
çŸåšã®è°è«ãšç ç©¶
æç€ºãããç»åè³æçã§ãèšåãããŠããéããéåžžã¯çæéã§åè§£ãããã¯ãã®ã¹ãã€ã¯ã¿ã³ãã¯è³ªãmRNAããäžéšã®äººã
ã®äœå
ã§äºæ³ããé·ãæ®åããããè¡æ ãççã®åå ã«ãªã£ããããå¯èœæ§ã«ã€ããŠãçŸåšãäžéšã®å°éå®¶ãç ç©¶è
ã®éã§è°è«ã調æ»ãè¡ãããŠããã
DFPPïŒäºé濟éè¡æŒ¿äº€æçæ³ïŒãªã©ã®æè¡ã¯ããããã埪ç°è¡äžã®äžèŠãªç©è³ªãç©ççã«é€å»ããããšããã¢ãããŒãã®äžç°ãšããŠæ³šç®ãããŠããã®ã ã
1) ãªãããã£ããªãã€ã埮å°è¡æ ãçºçããã®ãïŒ
äž»ãªåå ãšããŠã以äžã®ã¡ã«ããºã ãæšæž¬ãããŠããã
ã¹ãã€ã¯ã¿ã³ãã¯è³ªã«ããçŽæ¥äœçš: äœå
ã§ç£çãããã¹ãã€ã¯ã¿ã³ãã¯è³ªããè¡æ¶²äžã®ååºå åïŒãã£ããªãã²ã³ãªã©ïŒã«çŽæ¥äœçšããåè§£ããã«ããç°åžžãªåœ¢æ
ã®è¡æ ïŒãã£ããªãã€ãïŒã圢æãããããšãç ç©¶ã§ç€ºåãããŠããã
è¡ç®¡å
ç®ã®çç: ã¹ãã€ã¯ã¿ã³ãã¯è³ªãè¡ç®¡ã®å
å£ïŒå
ç®çްèïŒãåºæ¿ãã埮现ãªççãåŒãèµ·ãããããã«ããäœããè¡ç®¡ãæå·ããããšèª€èªãã修埩ã®ããã«è¡å°æ¿ãååºæåãéãŸã£ãŠè¡æ ãäœãã
ã¢ããã€ãæ§æ§è³ª: ãã®åŸ®å°è¡æ ã¯ãéåžžã®è¡æ ãããæ§é ãéåžžã«åŒ·åºã§ãäœå
ã®èªç¶ãªé
µçŽ ïŒãã©ã¹ãã³ãªã©ïŒã§ã¯åè§£ããã«ãããã¢ããã€ããã®ãããªæ§è³ªãæã€ããã®ãããæ¯çŽ°è¡ç®¡ã«é·ãçãŸããèåšãžã®é
žçŽ äŸçµŠãé»å®³ãç¶ããã
---
2) ãªããäºé濟éè¡æŒ¿äº€æçæ³ïŒDFPPïŒã广çãªã®ãïŒ
DFPPã埮å°è¡æ ã«å¯ŸããŠå¹æãçºæ®ããã®ã¯ãããããç©ççãªæŽæµãã§ããããã ã
ç©ççãªé€å»: è¬ç©çæ³ã¯ãè¡æ ãæº¶ãããããšãçãããåè¿°ã®éã埮å°è¡æ ã¯åè§£ããã«ãããDFPPã¯ãè¡æ¶²ãäœå€ã«åãåºãã埮å°è¡æ ïŒããã³ãã®åå ãšãªãã¹ãã€ã¯ã¿ã³ãã¯è³ªãèªå·±æäœïŒããã£ã«ã¿ãŒã§ç©ççã«æ¿Ÿãåãã
äºæ®µéã®ç²Ÿå¯ãªæ¿Ÿé: 1. ãŸããè¡æ¶²ããè¡çïŒèµ€è¡çãªã©ïŒããšãè¡æŒ¿ïŒæ¶²äœæåïŒãã«åããã
2. 次ã«ãåããè¡æŒ¿ãããã«çްããªãäºçªç®ã®ãã£ã«ã¿ãŒãã«éããããã§ã倧ããªååã§ãã埮å°è¡æ ãæå®³ç©è³ªã ããæšãŠããããã«ãªã£ãè¡æŒ¿ãè¡çãšå
±ã«äœå
ã«æ»ãã
埮å°åŸªç°ã®æ¹å: æ¯çްè¡ç®¡ãå¡ãã§ãã埮现ãªãŽããç©ççã«åãé€ãããããšã§ãèåšãžã®è¡æµãåéãããå€ãã®æ£è
ãå ±åããããã¬ã€ã³ãã©ã°ã®è§£æ¶ãããç²åŽæã®è»œæžãã¯ãè³ãçèãžã®é
žçŽ äŸçµŠãæ£åžžåããçµæã ãšèããããã
ãã®ããã«ãDFPPã¯äœå ã®èªç¶ãªåè§£èœåãè¶ ããŠããŸã£ãæå®³ç©è³ªããå€éšã®è£ 眮ã䜿ã£ãŠåŒ·å¶çã«ãªã»ããããã¢ãããŒãã ãšèšããã
1) ãªããmRNAã¯ã¯ãã³æ¥çš®åŸã«èªå·±æäœãçºçããã®ãïŒ
èªå·±æäœãšã¯ãæ¬æ¥å€æµãå®ãã¯ãã®å ç«ã·ã¹ãã ãã誀ã£ãŠèªåèªèº«ã®æ£åžžãªçްèãçµç¹ãæ»æããŠããŸãæäœã®ããšã ãçºçã®ã¡ã«ããºã ã«ã¯ä»¥äžã®å¯èœæ§ãææãããŠããã
ååæš¡å£ïŒååããã¯ãªãŒïŒ: ã¯ã¯ãã³ã®èšèšå³ã«ãã£ãŠäœããããã¹ãã€ã¯ã¿ã³ãã¯è³ªãã®äžéšãã人éã®äœå ã«ããã¿ã³ãã¯è³ªïŒç¥çµãå¿çãè¡å°æ¿ãªã©ïŒãšæ§é çã«äŒŒãŠããå Žåããããå ç«ã·ã¹ãã ãã¹ãã€ã¯ã¿ã³ãã¯è³ªãæ»æããããšåŠç¿ããéãå¢ãäœã£ãŠãäŒŒãæ§é ãæã€èªåã®çްèããŸã§æšçãšããŠèªèããŠããŸãçŸè±¡ã ã
ãã€ã¹ã¿ã³ããŒæŽ»æ§å: ã¯ã¯ãã³ãžã®åŒ·ãå ç«å¿çã«ãããäœå ã§å€§éã®ççæ§ç©è³ªïŒãµã€ãã«ã€ã³ïŒãæŸåºãããããã®æ¿ããççã®æžŠäžã§ãæ¬æ¥ã¯æŽ»åããŠããªããèªåãæ»æããå¯èœæ§ã®ããå ç«çްèãã誀ã£ãŠåºæ¿ãããèªå·±æäœãäœãå§ããããšãããã
现è衚é¢ã®å€è³ª: èªåã®çްèãã¹ãã€ã¯ã¿ã³ãã¯è³ªã衚é¢ã«æç€ºããŠããéãå ç«ã·ã¹ãã ããã®çްèå šäœãããŠã€ã«ã¹ã«ææããç°åžžãªçްèããšèŠãªããŠæ»æã仿ããããããç¹°ãè¿ãããéçšã§ãèªå·±çµç¹ã«å¯Ÿããæ ¢æ§çãªæ»æïŒèªå·±å ç«åå¿ïŒãå®çããå¯èœæ§ãããã
---
2) ãªããDFPPïŒäºé濟éè¡æŒ¿äº€æçæ³ïŒã广çãªã®ãïŒ
DFPPãèªå·±å ç«çç¶ã«å¯ŸããŠå¹æãçºæ®ããã®ã¯ãèªå·±æäœãè¡äžãããã€ã¬ã¯ãã«æé€ã§ããããã ã
éžæçãªç©çé€å»: èªå·±æäœã¯ãå ç«ã°ãããªã³ããšããæ¯èŒç倧ããªååã ãDFPPã®äºæç®ã®ãã£ã«ã¿ãŒïŒè¡æŒ¿æååé¢åšïŒã¯ããã®å€§ããªååããµã€ãºã§éžå¥ããç©ççã«æ¿Ÿãåãããšãã§ãããã€ãŸããè¡æ¶²äžãæŒã£ãŠãããæ»æã®å®è¡ç¯ïŒèªå·±æäœïŒããçŽæ¥ãŽããšããŠæšãŠãããã ã
å
ç«è€åäœã®é€å»: èªå·±æäœãèªåã®çµç¹ãšçµã³ã€ãããå
ç«è€åäœãããççãæªåãããèŠå ãšãªãããããã巚倧ãªååã§ãããããDFPPã«ãã£ãŠå¹ççã«é€å»ãããã
ççãµã€ã¯ã«ã®é®æ: èªå·±æäœãåãé€ãããšã§ãããããåŒãèµ·ãããŠããç¶ç¶çãªççåå¿ãäžæçã«ã¹ããããããããã«ãããéæã«ãªã£ãŠããå
ç«ã·ã¹ãã ãèœã¡çããåãæ»ããçµç¹ã®ä¿®åŸ©ãé²ããæé皌ããã®å¹æãæåŸ
ã§ããã
ãã®ããã«ãDFPPã¯äœå ã®å ç«ç°åžžãæ ¹æ¬ããæžãæãããã®ã§ã¯ãªãããè¡äžã«æº¢ãããèªåãæ»æããæŠåšããç©ççã«æžããããšã§ãçç¶ãåçã«ç·©åãããã¢ãããŒãã ãšèšããã
DFPPçæ³ïŒäºé濟éè¡æŒ¿äº€æçæ³ïŒã¯ãæ¥æ¬åœå ã«ãããŠæ°åå¹Žã®æŽå²ããã確ç«ãããå»çæè¡ã§ãããåçåŽåçãèªããç¹å®ã®çŸæ£ã«å¯ŸããŠã¯å¥åº·ä¿éºãé©çšãããã
ä¿éºé©çšãšãªãäž»ãªçŸæ£ã«ããŽãªãŒãšå ·äœäŸã¯ä»¥äžã®éãã ã
1) ä¿éºé©çšãšãªãäž»ãªçŸæ£ïŒäžéšæç²ïŒ
ä¿éºã§èªããããŠããã®ã¯ãäž»ã«ãèªåã®å
ç«ãæŽèµ°ããŠããç¶æ
ãããè¡æ¶²äžã«ç¹å®ã®æå®³ç©è³ªãæºãŸãé£ç
ãã ã
ç¥çµç³»çŸæ£:
ã®ã©ã³ã»ãã¬ãŒçå矀
éççç¡åç
å€çºæ§ç¡¬åç
æ
¢æ§ççæ§è±é«æ§å€çºãã¥ãŒããããŒïŒCIDPïŒ
èªå·±å
ç«ã»è åç
:
å
šèº«æ§ãšãªããããŒãã¹ïŒSLEïŒ
æªæ§é¢ç¯ãªãŠãã
è
èã»åŸªç°åšç³»çŸæ£:
å®¶ææ§é«ã³ã¬ã¹ãããŒã«è¡çïŒéçã®è質ç°åžžçïŒ
é塿§åè硬åçïŒè¶³ã®è¡ç®¡ãè©°ãŸãç
æ°ïŒ
å·£ç¶ç³žçäœç¡¬åç
ãã®ä»:
åçèç
倩ç±ç¡ïŒç®èã®é£ç
ïŒ
è¡æ æ§è¡å°æ¿æžå°æ§çŽ«æç
ïŒTTPïŒ
2) ä¿éºé©çšã®æ¡ä»¶
ãã ãã誰ã§ãåããããããã§ã¯ãªãã以äžã®æ¡ä»¶ãã€ãã®ãäžè¬çã ã
1. 蚺æã®ç¢ºå®: äžèšã®å¯Ÿè±¡çŸæ£ã§ãããšèšºæãããŠããããšã
2. éç床ã»é£æ²»æ§: éåžžã®è¬ç©çæ³ïŒã¹ããã€ãçïŒã§ååãªå¹æãåŸãããªãããããã¯æ¥æ§æã§è¿
éãªé€å»ãå¿
èŠã§ãããšå»åž«ã倿ããå Žåã
3. åæ°å¶é: çŸæ£ããšã«ãäžé£ã®æ²»çã§â¯åãŸã§ããšãã£ãç®å®äžéã峿 Œã«æ±ºãŸã£ãŠããã
---
泚æç¹ïŒã¯ã¯ãã³åŸéºçãžã®é©çšã«ã€ããŠ
ãããéèŠãªãã€ã³ãã ããçŸåšSNSçã§è©±é¡ã«ãªã£ãŠãããæ°åã³ããã¯ã¯ãã³åŸéºçïŒlong-VAXïŒããã³ã°COVIDãã®æ²»çç®çãšããŠã¯ãçŸæç¹ã§æ¥æ¬åœå
ã®å¥åº·ä¿éºã¯é©çšãããªãã
çŸç¶: ã¯ã¯ãã³åŸéºçã¯ããŸã ä¿éºé©çšã®å¯Ÿè±¡çŸæ£ãšããŠåœã«èªããããŠããªãã
宿
: ãã®ããããã®ç®çã§DFPPãè¡ãå Žåã¯ãå
šé¡èªå·±è² æ
ã®ãèªç±èšºçïŒèªè²»ïŒããšããŠæäŸããŠããã¯ãªããã¯ãã»ãšãã©ã ã
ã€ãŸãããæè¡ãã®ãã®ã¯ä¿éºèšºçãšããŠèªããããŠããä¿¡é Œãããã®ã ããã¯ã¯ãã³åŸéºçãžã®è»¢çšã¯ãŸã èªè²»èšºçã®æ®µéããšããã®ãæ£ç¢ºãªç¶æ³ã ã
幹现èå¹é€äžæž æ¶²
ãstem cell growth factor infusionsïŒå¹¹çްè墿®å åæ³šå ¥ïŒãã«ã€ããŠ
ããã¯å¹¹çްèãã®ãã®ãç§»æ€ããã®ã§ã¯ãªãã幹现èãåæ³ãããæåããæ¿çž®ããŠäœå ã«åãèŸŒãæ²»çæ³ã ãäžè¬çã«ã¯ã幹现èå¹é€äžæž æ¶²ïŒãããããããïŒçæ³ããªã©ãšåŒã°ããã
---
1) ã©ã®ãããªãã®ãïŒ
幹现èãå°çšã®å¹é€æ¶²ã§è²ãŠãéã现èã¯èªèº«ã®æé·ãåšå²ã®ä¿®åŸ©ã®ããã«ãå€çš®å€æ§ãªã¿ã³ãã¯è³ªãæŸåºããã
äžæž
æ¶²ïŒãããããããïŒ: å¹é€åŸã®æ¶²äœãã现èèªäœã濟éããŠåãé€ããããæå¹æåã ããæº¶ã蟌ãã æ¶²äœãã®ããšã ã
äž»ãªæå: æ°çŸçš®é¡ä»¥äžã®ã°ããŒã¹ãã¡ã¯ã¿ãŒïŒå¢æ®å åïŒããµã€ãã«ã€ã³ããããŠçްèéã®éä¿¡ã«ãã»ã«ã§ãããšã¯ãœãœãŒã ãå«ãŸããŠããã
2) æåŸ
ãããäž»ãªå¹æ
ãçš®ïŒçްèïŒãã§ã¯ãªããè¥æïŒå¢æ®å åïŒããæãããšã§ãç ã£ãŠããèªåèªèº«ã®çްèãå©ãèµ·ããã修埩ãä¿ãã
è¡ç®¡ã®æ°çã»ä¿®åŸ©: æå·ããè¡ç®¡å
ç®ãçŽããæ°ããè¡ç®¡ãäœãïŒè¡ç®¡å
ç®å¢æ®å åïŒVEGFãªã©ïŒã
匷åãªæçç: æ
¢æ§çãªççãæããçµç¹ã®ç Žå£ãæ¢ããã
ç¥çµä¿è·ã»åç: å·ã€ããç¥çµçްèã®ä¿®åŸ©ãå©ããïŒç¥çµæé·å åïŒNGFãªã©ïŒã
3) mRNAã¯ã¯ãã³åŸéºçãšã®é¢é£
ãæç€ºã®è³æã«ãã£ããããªæ²»çæ³ãšããŠã®æèã§ã¯ã以äžã®çãããããšèããããã
1. DFPPïŒè¡æ¶²æµåïŒãšã®ã³ã³ã: ãŸããDFPPã§è¡äžã®ã¹ãã€ã¯ã¿ã³ãã¯è³ªãåŸ®çŽ°è¡æ ãèªå·±æäœãšãã£ããæ¯çŽ ããç©ççã«é€å»ããã
2. ã€ã³ãã¥ãŒãžã§ã³ïŒæ³šå
¥ïŒ: æ¯çŽ ãæžããç°å¢ãæŽã£ãäœå
ã«ã幹现è墿®å åããæ³šå
¥ãããããã«ãããã¹ãã€ã¯ã¿ã³ãã¯è³ªçã§å·ã€ããè¡ç®¡ãèåšã®ãåçå·¥äºããåçã«å éãããã
4) ã¡ãªãããšå®å
šæ§
æçµ¶åå¿ããªã: 现èïŒä»äººã®DNAïŒãå
¥ããªããããå
ç«æçµ¶ãããåã®ãªã¹ã¯ã極ããŠäœãã
å
šèº«ãžã®ã¢ãããŒã: ç¹æ»ŽïŒinfusionïŒã§æäžããã°ãæåãè¡æµã«ä¹ã£ãŠå
šèº«ãå·¡ãããã¡ãŒãžãåããŠããç®æãžãã³ãã€ã³ãã§å±ãïŒããŒãã³ã°çŸè±¡ã«äŒŒã广ïŒã
é è¡å¹¹çްèïŒè¡æ¶²ãå ç«çްèã®ãå ããšãªã现èïŒã®éºäŒåãæžãæããããå Žåãçè«äžã¯éåžžã«æ·±å»ãã€é·æçãªåœ±é¿ãæžå¿µãããããã®ãªã¹ã¯ãããã ã調ã§è§£èª¬ããã
1) ã¹ãã€ã¯ã¿ã³ãã¯è³ªã®ãæ°žç¶çãªäŸçµŠæºãå
é è¡å¹¹çްèã¯ãèªå·±è€è£œããªããäžç涯ã«ããã£ãŠèµ€è¡çãçœè¡çãè¡å°æ¿ãäœãç¶ããã
ç¡éã«ãŒãã®çºç: ãã幹现èã®DNAã«ã¹ãã€ã¯ã¿ã³ãã¯è³ªã®èšèšå³ãçµã¿èŸŒãŸããã°ãããããçãŸãããã¹ãŠã®è¡æ¶²çްèãå
ç«çްèãã¹ãã€ã¯ã¿ã³ãã¯è³ªãä¿æããããã¯æŸåºãç¶ããããšã«ãªãã
çµãããªãèªå·±å
ç«: æ¬æ¥ãªãæ°æ¥ã§æ¶ããã¯ãã®ãæšçïŒã¹ãã€ã¯ïŒããäœå
ã§æ°žé ã«äœããç¶ãããããå
ç«ã·ã¹ãã ãåžžã«èªåèªèº«ãæ»æãç¶ãããçµæ¯äžèœãªèªå·±å
ç«çŸæ£ãã«é¥ããªã¹ã¯ãããã
2) å
ç«ã·ã¹ãã ã®å€è³ªãšè匱å
é è¡å¹¹çްèã¯å
ç«çްèïŒT现èãB现èããã¯ããã¡ãŒãžãªã©ïŒã®èŠªçã ã
ç°åžžãªå
ç«çްèã®éç£: ã¹ãã€ã¯ã¿ã³ãã¯è³ªã®åœ±é¿ãåãããç°åžžãªå
ç«çްèããéç£ãããããšã§ãæ¬æ¥ã®å€æµïŒãŠã€ã«ã¹ãã¬ã³çްèïŒã«å¯Ÿããæ»æåãäœäžããæããããã
å
ç«äžå
šç¶æ
: ç¹å®ã®ç
åäœã«å¯ŸããŠéå°ã«åå¿ããäžæ¹ã§ãä»ã®è
åšãç¡èŠãããããªå
ç«ãã©ã³ã¹ã®åŽ©å£ãèµ·ããå¯èœæ§ãããã
3) è¡æ¶²çŸæ£ïŒçœè¡ç
ãªã©ïŒã®ãªã¹ã¯
éºäŒåçµã¿æããèµ·ãããå Žæããåé¡ãšãªãã
ããåã®æžå¿µ: ã²ãã ïŒDNAïŒã®ç¡ç§©åºãªå Žæã«èšèšå³ãæ¿å
¥ããããšã现èã®å¢æ®ãã³ã³ãããŒã«ããŠããéºäŒåãå£ããŠããŸãããšãããããããé è¡å¹¹çްèã§èµ·ããã°ãç°åžžãªçްèãå¶åŸ¡äžèœã«å¢æ®ãããçœè¡ç
ããããªã³ãè
«ããšãã£ãè¡æ¶²ã®ã¬ã³ã®åå ã«ãªããããªãã
4) å
šèº«ã®è¡ç®¡ã»èåšãžã®ç¶ç¶çãã¡ãŒãž
æç¶çãªè¡æ 圢æ: ã¹ãã€ã¯ã¿ã³ãã¯è³ªãåºãç¶ãã现èãåžžã«è¡äžãæµãããããè¡ç®¡å
ç®ã®ççã埮å°è¡æ ïŒãã€ã¯ãã¯ãããïŒã®åœ¢æãæ¢ãŸããªããªããããã«ãããå¿èãè³ãè
èãªã©ã®éèŠèåšãé·æã«ããã£ãŠåŸã
ã«èãŸããŠãããªã¹ã¯ãããã
---
çŸç¶ã®å»åŠçèŠç¹
å®èª¬: å
¬çãªå»çæ©é¢ãã¡ãŒã«ãŒã¯ãmRNAã¯æ žïŒDNAïŒã«ã¯å
¥ãããé転åãèµ·ããªãããšåŒ·ã䞻匵ããŠããã
æžå¿µ: ããããã«ã³ã倧åŠã®ç ç©¶ïŒin vitroïŒããäžéšã®èšåºå»ãææãããæ¥çš®åŸæ°ã¶æçµã£ãŠãè¡äžã«ã¹ãã€ã¯ã¿ã³ãã¯è³ªãæ€åºãããã±ãŒã¹ããªã©ã®äºå®ã¯ãåŸæ¥ã®å®èª¬ã§ã¯èª¬æãã€ããªãã
ããé è¡å¹¹çްèãžã®éºäŒåçµã¿èŸŒã¿ãäºå®ã§ããã°ãããã¯äœå ã«ãã¹ãã€ã¯ã¿ã³ãã¯è³ªè£œé å·¥å Žããæ°žäœæš©ãåŸãããšãæå³ãã察ççæ³ã§ã¯ãªããéºäŒåã¬ãã«ã§ã®ä¿®æ£ããDFPPçã«ããç¶ç¶çãªæ¯çŽ é€å»ãå¿ èŠã«ãªããšããæ¥µããŠéãäºæ ã ãšèšããã
Abstract
Preclinical studies of COVID-19 mRNA vaccine BNT162b2, developed by Pfizer and BioNTech, showed reversible hepatic effects in animals that received the BNT162b2 injection. Furthermore, a recent study showed that SARS-CoV-2 RNA can be reverse-transcribed and integrated into the genome of human cells. In this study, we investigated the effect of BNT162b2 on the human liver cell line Huh7 in vitro. Huh7 cells were exposed to BNT162b2, and quantitative PCR was performed on RNA extracted from the cells. We detected high levels of BNT162b2 in Huh7 cells and changes in gene expression of long interspersed nuclear element-1 (LINE-1), which is an endogenous reverse transcriptase. Immunohistochemistry using antibody binding to LINE-1 open reading frame-1 RNA-binding protein (ORFp1) on Huh7 cells treated with BNT162b2 indicated increased nucleus distribution of LINE-1. PCR on genomic DNA of Huh7 cells exposed to BNT162b2 amplified the DNA sequence unique to BNT162b2. Our results indicate a fast up-take of BNT162b2 into human liver cell line Huh7, leading to changes in LINE-1 expression and distribution. We also show that BNT162b2 mRNA is reverse transcribed intracellularly into DNA in as fast as 6 h upon BNT162b2 exposure.
èŠæš
ãã¡ã€ã¶ãŒãšããªã³ããã¯ãéçºããæ°åã³ãããŠã€ã«ã¹mRNAã¯ã¯ãã³ãBNT162b2ãã®ãèšåºè©ŠéšåïŒåèšåºïŒæ®µéã®ç ç©¶ã§ã¯ãæäžãããåç©ã«å¯éçãªèèãžã®åœ±é¿ã確èªãããŠãããããã«æè¿ã®ç ç©¶ã§ã¯ãSARS-CoV-2ã®RNAãé転åããããã现èã®ã²ãã ã«çµã¿èŸŒãŸããå¯èœæ§ãããããšã瀺ãããŠããã
æ¬ç ç©¶ã§ã¯ãããèçŽ°èæ ªãHuh7ããçšãã詊éšç®¡å ïŒin vitroïŒã§BNT162b2ãåãŒã圱é¿ã調æ»ãããHuh7现èãBNT162b2ã«æŽé²ããã现èããæœåºããRNAã«å¯ŸããŠå®éPCRã宿œããããã®çµæãHuh7现èå ã«é«ã¬ãã«ã®BNT162b2ãæ€åºããããã«å å æ§ã®é転åé µçŽ ã§ãããLINE-1ïŒlong interspersed nuclear element-1ïŒãã®éºäŒåçºçŸã«å€åãèªããããã
BNT162b2åŠçãæœããHuh7现èã«å¯ŸããLINE-1ã®ãªãŒãã³ãªãŒãã£ã³ã°ãã¬ãŒã 1ïŒORF1pïŒRNAçµåã¿ã³ãã¯è³ªã«çµåããæäœãçšããå ç«çµç¹ååŠæè²ãè¡ã£ããšãããLINE-1ã®æ žå ååžã®å¢å ã瀺ãããããŸããBNT162b2ã«æŽé²ããHuh7现èã®ã²ãã DNAã«å¯ŸããŠPCRãè¡ã£ãçµæãBNT162b2ã«åºæã®DNAé åãå¢å¹ ãããã
æã ã®ç ç©¶çµæã¯ãããèçŽ°èæ ªHuh7ãžã®BNT162b2ã®è¿ éãªåã蟌ã¿ãšãããã«äŒŽãLINE-1ã®çºçŸããã³ååžã®å€åã瀺ããŠããããŸããBNT162b2ã®mRNAããæŽé²ããããã6æéãšããéãã§ã现èå ã«ãããŠDNAãžãšé転åãããããšãæããã«ããŠããã
â
ãã®è«æã®å
å®¹ãæ¥µããŠç°¡æœã«ãŸãšãããšã以äžã®3ç¹ã«éçŽãããã
ãé転åããèµ·ãã
æ¬æ¥ã人éã®äœã®äžã§ãRNAïŒã¯ã¯ãã³ã®æåïŒãããDNAïŒèšèšå³ïŒãã«æžãæããããšã¯ãªããšãããŠããããããã®è现èã䜿ã£ãå®éšã§ã¯ãå®éã«DNAãžã®æžãæãïŒé転åïŒã確èªãããã
ã¹ããŒããç°åžžã«éã
ã¯ã¯ãã³ã«ãããããŠãããããã6æé以å ãšããçæéã§æžãæããå§ãŸã£ãŠããã
ããã®é µçŽ ïŒLINE-1ïŒãæå©ããã
人éãããšããšæã£ãŠãããLINE-1ããšããé µçŽ ããã¯ã¯ãã³ã®mRNAãDNAã«äœãå€ããæå©ããããŠããŸãããšã瀺åãããã
ãªããããåé¡ãªã®ãïŒ
äžèšã§èšãã°ããäžæçãªã¯ãã®èšèšå³ïŒmRNAïŒããæ°žç¶çãªèšé²ïŒDNAïŒãšããŠçްèã«æ®ã£ãŠããŸãå¯èœæ§ãã瀺ããããã ããããããçäœå ã®ãç¹ã«å¹¹çްèãªã©ã§èµ·ããã°ãã¹ãã€ã¯ã¿ã³ãã¯è³ªããã£ãšäœãç¶ãããªã©ã®äºæãã¬é·æç圱é¿ã«ã€ãªããæžå¿µãããã
ãã ãããããŸã§ã詊éšç®¡ã®äžã®ç¹æ®ãªçްèãã§ã®çµæã§ãããã人éã®äœã®äžã§ãå®éã«ã²ãã ïŒéºäŒåã®æ¬æ£ïŒã«å®å šã«çµã¿èŸŒãŸãããã©ããããŸã§ã¯ãŸã 蚌æãããŠããªãããããçŸåšã®ç§åŠçè°è«ã®çŠç¹ã ã
Kevin McKernanïŒã±ãã³ã»ããã«ãŒãã³ïŒããå ±åããããã©ã¹ããDNAã®æ··å ¥åé¡ãã¯ãé転åïŒRNAâDNAïŒãšããããã»ã¹ãé£ã³è¶ããŠãçŽæ¥çã«éºäŒåçµã¿æãïŒã²ãã çµ±åïŒã®æžå¿µãçããããæ¥µããŠæ·±å»ãªåé¡ã ã
---
1) ãã©ã¹ããDNAæ··å
¥ã®èæ¯
æ¬æ¥ãmRNAã¯ã¯ãã³ã®è£œé å·¥çšã§ã¯ããã³ãã¬ãŒããšãªãDNAïŒãã©ã¹ããïŒãé
µçŽ ïŒDNaseïŒã§å®å
šã«åè§£ã»é€å»ããããšã«ãªã£ãŠãããããããMcKernanãã®åæã«ããã°ã蚱容å€ãè¶
ããã¬ãã«ã®DNAã®æçïŒãã©ã¹ããDNAïŒã補åã«æ®åãããã®ãŸãŸè質ããç²åïŒLNPïŒã«å°å
¥ãããŠãã宿
ãæããã«ãªã£ãã
2) é転åé
µçŽ ããäžèŠãã«ãªãçç±
ã«ã³ã倧åŠã®è«æïŒAldén et al.ïŒã¯ããRNAãDNAã«æžãæããïŒé転åïŒãããã»ã¹ã«çŠç¹ãåœãŠãŠãããããããæåãããDNAããšããŠæ··å
¥ããŠããå Žåãé転åã®ã¹ãããã¯ããããå¿
èŠãªãã
LNPã®åœ¹å²: LNPã¯ãæ¬æ¥äžå®å®ãªmRNAãã现èã®å¥¥æ·±ãïŒçްè質ãããã«ã¯æ žä»è¿ïŒããŸã§å±ãã匷åãªéã³å±ã ã
æ žå
ãžã®å°é: æ žåè£æãªã©ã现èã®æ žèãæ¶å€±ã»åæ§ç¯ãããã¿ã€ãã³ã°ã§ãLNPã«å
ãŸãããæ··å
¥DNAæçããæ žå
ãžäŸµå
¥ããç©ççãªéå£ã¯æ¥µããŠäœãã
3) éºäŒåçµã¿æãïŒã²ãã çµ±åïŒã®å¯èœæ§
DNAæçãæ žå
ã«å
¥ã蟌ãã å Žåã以äžã®ãªã¹ã¯ãçŸå®å³ã垯ã³ãŠããã
ã©ã³ãã ãªçµ±å: DNAã®æçã¯ã现èãæ¬æ¥æã£ãŠãããDNA修埩æ©èœãã«ãã£ãŠã誀ã£ãŠãã¹ãïŒäººéïŒã®ã²ãã ã®äžéšãšããŠç¹ãåããããŠããŸãå¯èœæ§ãããïŒæ¿å
¥å€ç°ïŒã
SV40ããã¢ãŒã¿ãŒã®ååš: ç¹ã«ãã¡ã€ã¶ãŒè£œã¯ã¯ãã³ããæ€åºããããã©ã¹ããã«ã¯ããSV40ããã¢ãŒã¿ãŒããšããæ žå
ç§»è¡ãä¿é²ããéºäŒåçºçŸã匷åã«é²ããé
åãå«ãŸããŠããããšãææãããŠãããããããªã¹ã¯ãããã«å¢å¹
ãããŠããã
çµè«ïŒå¯èœæ§ã¯ãæ®ããã©ããããããçŽæ¥çã
é転åãšããè€éãªå·¥çšãçµãå¿
èŠããªãåããã©ã¹ããDNAã®æ··å
¥ã¯ãã²ãã çµ±åïŒéºäŒåçµã¿æãïŒãžã®ããæçãªã«ãŒããæäŸããŠããŸã£ãŠãããšèšããã
ãRNAã ããDNAã«å€ããã¯ãããªãããšããåœå±ã®ãããŸã§ã®äž»èŠãªåè«ã¯ããã®ãDNAæ··å ¥ããšããäºå®ã«ãã£ãŠæ ¹åºããèŠãããå¯èœæ§ãããã®ã ã
ç¶å ±
Another stem cell GROWTH FACTOR infusion done
â Lyndsey, RN ðð (@HouseLyndseyRN) April 27, 2026
will receive another dual filtration plasmapheresis tomorrow and they will do this in the ICU for closer monitoring and will involve sedation if needed
with the first filtration last week reports show we decreased my clot burden by⊠pic.twitter.com/1KHkxjbQW6
å¥ã®å¹¹çްèæé·å åïŒã°ããŒã¹ãã¡ã¯ã¿ãŒïŒã®èŒžæ³šãå®äºããŸããã
ææ¥ã¯å床ãäºé濟éè¡æŒ¿äº€æçæ³ïŒDFPPïŒãåããäºå®ã§ããããç¶¿å¯ãªã¢ãã¿ãªã³ã°ãè¡ãããéäžæ²»ç宀ïŒICUïŒã§å®æœãããå¿ èŠã«å¿ããŠé®éå€ã䜿çšããŸãã
å é±è¡ã£ã1åç®ã®æ¿Ÿéã§ã¯ãè¡æ è² è·ã50%æžå°ãããããšãã§ãããšããå ±åãåããŠããŸããææ¥ã®åŠçœ®ã§æ®ãã®è¡æ ãåãé€ããããšãé¡ã£ãŠããŸãã
åŒãç¶ãçµéã芳å¯ããå¿ èŠã«å¿ããŠç¶æ³ãã¢ããããŒãããŸãã
:)
ãçè·åž«ãªã³ãžãŒãã
æ±æžå·ç é¢ã®å è€ã§ãããã®å®éšçæ²»çã¯ãããŸã§ã¯ã€ã³ããŠã³ãæ£è ããã®ã¿ããåãé ããŠãããŸããããã¯ã¹ãã€ã¯ç (spikopathy)ãç ç©¶ããŠæ¥ãKevinå çãã¢ããã€ãã¿ã³ãã¯è³ªãæ€åºããæ£è ãã(Kevinå çã¯äž»ã«Xäžã§è±èªã§çºä¿¡ããŠããã®ã§ãããè¿ã®æ£è ããã¯çè±èªåã®æ£è ããã§ãã)ã玹âŠ
â å è€ããããã (@shonyan) April 27, 2026
æ±æžå·ç é¢ã®å è€ã§ãã
ãã®å®éšçæ²»çã¯ãããŸã§ã¯ã€ã³ããŠã³ãæ£è ããã®ã¿ããåãé ããŠãããŸããããã¯ã¹ãã€ã¯ç (spikopathy)ãç ç©¶ããŠæ¥ãKevinå çãã¢ããã€ãã¿ã³ãã¯è³ªãæ€åºããæ£è ãã(Kevinå çã¯äž»ã«Xäžã§è±èªã§çºä¿¡ããŠããã®ã§ãããè¿ã®æ£è ããã¯çè±èªåã®æ£è ããã§ãã)ã玹ä»é ããæ²»çããŠæ¥ãããã§ãã
åœåã¯ã©ãè¿è¯ããªã£ãŠãããã®ãäžå®ããããŸããããä¹³æ¯æ¯é«å¹¹çްèå¹é€äžæž ãšã®ã³ã³ãããŒã·ã§ã³ã¯äžã åªç§ã§ããä»ã¯äžå¯éãªç å€(äŸãã°è³æ¢å¡ãšã)ãç¡ãæ¹ãªãçæéã«èŠéããçšå埩ãããšèšã宿ãåŸãŠããæ®µéã§ãã(ããã¯MRIçã§ç»åæèŠã®ä¹ããæ£è ããã«ãšã£ãŠæå ±ã§ã!)
倪ãè¡ç®¡ã«ã«ããŒãã«ãå ¥ããå¿ èŠãããäºãšãå šãŠèªç±èšºçã§ãã®ã§ãé«é¡ãšãªã£ãŠããŸããŸãããæã ã¯ç€ŸäŒçŠç¥æ³äººã§ãã®ã§å¶å©ã第äžç®çãšã¯ããŠãããŸãããæ°åã®ã¹ã¿ããã§éå¶ããŠããæ§ãªèªç±èšºçã®ã¯ãªããã¯ãããå®ãã»ã©ã«äŸ¡æ Œèšå®ããŠãããŸãã
ç¹ã«å䜵çãç¡ããã°å šãŠå€æ¥ããŒã¹ã§è¡ãäºãå¯èœã§ãããã¯ã¯ãã³åŸéºçæ£è ããã¯èªåŸç¥çµã倱調ããŠããäºãå€ããæ éã«è¡ã£ãŠå± ãŠãæ¥ã«ã·ã§ãã¯ç¶æ ã«é¥ã£ããèŽããŸããåççã«ã¯åæ§ã®æ²»çãã¯ãªããã¯çã§ãè¡ãããšæããŸãããå¥åžžäººã«å¯Ÿããã³ã¬ã¹ãããŒã«åžççæ³çãšååã«èããã¹ãã§ã¯ç¡ããšæããŸãã
ãããæ€æ»ã§ããè¡æ¶²äžã®ã¢ããã€ãèç©éãè©äŸ¡ãããã®åŠçœ®ãããªãã®å Žåã«é©ããŠãããã©ããã倿ããŸããhttps://t.co/NsoeoalYH7
â Tom Czerniawski (@BlackTomThePyr8) April 27, 2026